CR20180490A - Celulas t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer - Google Patents
Celulas t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancerInfo
- Publication number
- CR20180490A CR20180490A CR20180490A CR20180490A CR20180490A CR 20180490 A CR20180490 A CR 20180490A CR 20180490 A CR20180490 A CR 20180490A CR 20180490 A CR20180490 A CR 20180490A CR 20180490 A CR20180490 A CR 20180490A
- Authority
- CR
- Costa Rica
- Prior art keywords
- present description
- peptides
- cells
- methods
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
La presente descripción se refiere a receptores de linfocito T (TCR) que se unen a antígenos asociados a tumor (TAA) y que permiten reconocer específicamente célu-las cancerosas, a linfocitos T que expresan los mismos, a métodos para producir los mismos, y a métodos para tratar cánceres con los mismos. En particular, la presente descripción se refiere a varios TCR y a sus variantes que se unen a moléculas de HLA de clase I o II unidas con un péptido, como el IGF2BP3-001 dotado de la se-cuencia de aminoácidos KIQEILTQV (SEQ ID N.º 1). La presente descripción se re-fiere, además, a péptidos, proteínas, ácidos nucleicos y células destinados a la utili-zación en métodos inmunoterapéuticos. En particular, la presente descripción se re-fiere a la inmunoterapia contra el cáncer. La presente descripción se refiere, ade-más, a epítopos peptídicos para linfocitos T que están asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308970P | 2016-03-16 | 2016-03-16 | |
| GBGB1604494.3A GB201604494D0 (en) | 2016-03-16 | 2016-03-16 | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| PCT/EP2017/056289 WO2017158116A1 (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180490A true CR20180490A (es) | 2019-01-10 |
Family
ID=55952419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180490A CR20180490A (es) | 2016-03-16 | 2017-03-16 | Celulas t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10537624B2 (es) |
| EP (1) | EP3430037B1 (es) |
| JP (1) | JP6929867B2 (es) |
| KR (1) | KR102266721B1 (es) |
| CN (1) | CN108884143A (es) |
| AU (1) | AU2017235069B2 (es) |
| BR (1) | BR112018067989A2 (es) |
| CA (1) | CA3017419A1 (es) |
| CR (1) | CR20180490A (es) |
| EA (1) | EA201891759A1 (es) |
| GB (1) | GB201604494D0 (es) |
| MA (2) | MA43328B2 (es) |
| MX (1) | MX2018011223A (es) |
| PE (1) | PE20190124A1 (es) |
| SG (1) | SG11201807590SA (es) |
| TW (1) | TWI788284B (es) |
| UA (1) | UA124532C2 (es) |
| WO (1) | WO2017158116A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| PL3430037T3 (pl) * | 2016-03-16 | 2022-12-19 | Immatics Biotechnologies Gmbh | Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej |
| TW201835100A (zh) * | 2017-02-06 | 2018-10-01 | 國立研究開發法人國立癌症研究中心 | 新穎ｔ細胞受體 |
| BR112020006643A2 (pt) | 2017-10-03 | 2020-09-24 | Juno Therapeutics Inc | moléculas de ligação específica ao hpv |
| CA3090791A1 (en) | 2018-02-11 | 2019-08-15 | Memorial Sloan-Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| CN112004825A (zh) | 2018-02-12 | 2020-11-27 | 弗雷德哈钦森癌症研究中心 | 细胞周期蛋白a1特异性t细胞受体及其用途 |
| JP7412006B2 (ja) * | 2018-03-14 | 2024-01-12 | メディジーン イミュノテラピーズ ゲーエムベーハー | 誘導性ｔ細胞レセプター及びその使用 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| AU2019249209A1 (en) * | 2018-04-05 | 2020-10-15 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| CA3113536A1 (en) | 2018-09-21 | 2020-03-26 | Xlifesc, Ltd. | High affinity t cell receptor for recognizing afp antigen |
| WO2020123388A1 (en) * | 2018-12-11 | 2020-06-18 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| US11644459B2 (en) | 2018-12-20 | 2023-05-09 | Ava Lifescience Gmbh | Method for selecting biological binding molecules |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| WO2020257553A1 (en) * | 2019-06-20 | 2020-12-24 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| CN110357953B (zh) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | 识别人巨细胞病毒pp65抗原的TCR |
| WO2021022044A1 (en) * | 2019-07-31 | 2021-02-04 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CA3154287A1 (en) * | 2019-09-12 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20230226181A1 (en) * | 2020-06-22 | 2023-07-20 | Nanjing Legend Biotech Co., Ltd. | GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| KR20230135589A (ko) | 2020-12-31 | 2023-09-25 | 이매틱스 유에스 인코포레이티드 | Cd8 폴리펩타이드, 조성물 및 이의 사용 방법 |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| AU2014271235B2 (en) * | 2008-10-01 | 2017-03-02 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| PL2172211T3 (pl) | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| IL286786B (en) * | 2012-09-14 | 2022-09-01 | The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst | T cell receptors that recognize mhc mage–a3 are restricted type ii |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
-
2016
- 2016-03-16 GB GBGB1604494.3A patent/GB201604494D0/en not_active Ceased
-
2017
- 2017-03-16 UA UAA201809121A patent/UA124532C2/uk unknown
- 2017-03-16 TW TW106108697A patent/TWI788284B/zh not_active IP Right Cessation
- 2017-03-16 JP JP2018548050A patent/JP6929867B2/ja not_active Expired - Fee Related
- 2017-03-16 PE PE2018001777A patent/PE20190124A1/es unknown
- 2017-03-16 WO PCT/EP2017/056289 patent/WO2017158116A1/en not_active Ceased
- 2017-03-16 US US15/461,020 patent/US10537624B2/en active Active
- 2017-03-16 KR KR1020187029658A patent/KR102266721B1/ko not_active Expired - Fee Related
- 2017-03-16 EA EA201891759A patent/EA201891759A1/ru unknown
- 2017-03-16 CN CN201780017419.XA patent/CN108884143A/zh active Pending
- 2017-03-16 MA MA43328A patent/MA43328B2/fr unknown
- 2017-03-16 MA MA45309A patent/MA45309B1/fr unknown
- 2017-03-16 CA CA3017419A patent/CA3017419A1/en not_active Abandoned
- 2017-03-16 EP EP17710963.4A patent/EP3430037B1/en active Active
- 2017-03-16 AU AU2017235069A patent/AU2017235069B2/en not_active Ceased
- 2017-03-16 CR CR20180490A patent/CR20180490A/es unknown
- 2017-03-16 MX MX2018011223A patent/MX2018011223A/es unknown
- 2017-03-16 BR BR112018067989-5A patent/BR112018067989A2/pt not_active IP Right Cessation
- 2017-03-16 SG SG11201807590SA patent/SG11201807590SA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017235069B2 (en) | 2020-05-07 |
| MX2018011223A (es) | 2018-11-22 |
| MA43328B2 (fr) | 2022-02-28 |
| KR20180122430A (ko) | 2018-11-12 |
| JP6929867B2 (ja) | 2021-09-01 |
| CN108884143A (zh) | 2018-11-23 |
| EA201891759A1 (ru) | 2019-02-28 |
| CA3017419A1 (en) | 2017-09-21 |
| AU2017235069A1 (en) | 2018-10-04 |
| EP3430037A1 (en) | 2019-01-23 |
| MA45309A (fr) | 2019-01-23 |
| BR112018067989A2 (pt) | 2019-02-05 |
| TWI788284B (zh) | 2023-01-01 |
| US20170312350A1 (en) | 2017-11-02 |
| MA45309B1 (fr) | 2023-01-31 |
| TW201742873A (zh) | 2017-12-16 |
| EP3430037B1 (en) | 2022-08-31 |
| SG11201807590SA (en) | 2018-10-30 |
| KR102266721B1 (ko) | 2021-06-17 |
| PE20190124A1 (es) | 2019-01-17 |
| JP2019512242A (ja) | 2019-05-16 |
| WO2017158116A1 (en) | 2017-09-21 |
| MA43328A1 (fr) | 2019-05-31 |
| UA124532C2 (uk) | 2021-10-05 |
| US10537624B2 (en) | 2020-01-21 |
| GB201604494D0 (en) | 2016-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20180490A (es) | Celulas t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer | |
| CO2018010808A2 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer | |
| CL2023001346A1 (es) | Uso de péptidos en inmunoterapia contra cáncer de pulmón amicrocítico y otros. | |
| CL2021002461A1 (es) | Péptido, anticuerpo y tcr que se unen al mismo, célula hospedadora, linfocito t activado, composición farmacéutica que los comprende, y sus usos en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) | |
| MX2018011225A (es) | Celulas t transfectadas y receptores de celulas t de utilidad en inmunoterapias contra el cancer. | |
| MX2020007808A (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer. | |
| CR20180398A (es) | Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga y otros tipos de cáncer | |
| CO2019002466A2 (es) | Nuevos péptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros tipos de cáncer | |
| AR121024A2 (es) | Péptido, ácido nucleico que lo codifica, anticuerpo, linfocito t, receptor de linfocito t, aptámero, célula hospedadora recombinante, composición farmacéutica y equipo | |
| CO2019012077A2 (es) | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer | |
| MX2018011220A (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer. | |
| CR20180591A (es) | Nuevos péptidos y nueva combinación de péptidos como dianas y para el uso en la inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer | |
| CO2021004270A2 (es) | Péptidos restringidos por b*44 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| CL2020002949A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer (divisional de la solicitud 201902878) | |
| CO2020013659A2 (es) | Péptidos restringidos por a*03 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| MX2021003089A (es) | Inmunoterapia con peptidos restringidos a a*01 y una combinacion de peptidos contra el cancer y metodos relacionados. | |
| CO2020013652A2 (es) | Péptidos para el uso en la inmunoterapia contra el cáncer | |
| CO2018011889A2 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cáncer | |
| CL2020002857A1 (es) | Nuevos péptidos (seq id no: 146) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cáncer (divisional de la solicitud no. 201802096) | |
| AR107897A1 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer | |
| AR110039A1 (es) | Péptidos y combinación de péptidos como dianas y para el uso en la inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer | |
| AR107898A1 (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer | |
| AR107117A1 (es) | Variantes del antígeno leucocitario humano (hla clase 1) y combinaciones de dichos péptidos para el uso en inmunoterapia contra el cáncer de mama y otros tipos de cáncer | |
| AR107025A1 (es) | Variantes de antígenos leucocitarios humanos (hla) de clase i para el uso en la inmunoterapia contra varios tipos de cáncer |